VAXCYTE, INC. Other Accrued Liabilities, Current
VAXCYTE, INC. (PCVX) had Other Accrued Liabilities, Current of $5.31 million as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes
us-gaap:OtherAccruedLiabilitiesCurrent · last filed 2026-02-24
- 2025-12-31: Other Accrued Liabilities, Current $5.31M.
- 2024-12-31: Other Accrued Liabilities, Current $1.98M; Other Accrued Liabilities, Current as first filed $2.08M.
- 2024-09-30: Other Accrued Liabilities, Current $3.96M.
- 2024-06-30: Other Accrued Liabilities, Current $2.27M.
| Period end | Other Accrued Liabilities, Current | Other Accrued Liabilities, Current as first filed |
|---|---|---|
| 2025-12-31 | $5.31M 10-K · filed 2026-02-24 | |
| 2024-12-31 | $1.98M 10-K · filed 2026-02-24 | $2.08M 10-K · filed 2025-02-25 |
| 2024-09-30 | $3.96M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $2.27M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $11.93M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $1.90M 10-K · filed 2025-02-25 | |
| 2023-09-30 | $2.49M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $1.91M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $2.70M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $1.41M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $1.58M 10-Q · filed 2022-11-07 | |
| 2022-06-30 | $925.00K 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $970.00K 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $3.66M 10-K · filed 2023-02-27 | $3.35M 10-K · filed 2022-02-28 |
| 2021-09-30 | $5.05M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $3.96M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $671.00K 10-Q · filed 2021-05-11 | |
| 2020-12-31 | $432.00K 10-K · filed 2022-02-28 | |
| 2020-09-30 | $415.00K 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $290.00K 10-Q · filed 2020-08-12 | |
| 2019-12-31 | $64.00K 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |